- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Granules India reports 23 percent rise in Q3 profit
![Granules India reports 23 percent rise in Q3 profit Granules India reports 23 percent rise in Q3 profit](https://medicaldialogues.in/h-upload/2022/11/12/750x450_190675-share-new.webp)
Granules, which also makes anti-inflammatory drug Ibuprofen, said 45.6 percent of its revenue came from finished dosages, the final ready-for-consumption product - its biggest segment.
Bengaluru: Pharmaceutical company Granules India Ltd, reported a 23 percent rise in third-quarter profit on Tuesday, propelled by strong demand for the painkiller drug Paracetamol.
Consolidated profit rose to 1.24 billion rupees ($15.22 million) for the three months ended Dec. 31, from 1.01 billion rupees a year earlier.
Consolidated revenue for the company rose nearly 15 percent to 11.46 billion rupees, "primarily driven by higher Paracetamol API sales in the US," the company said in an exchange filing.
"Opportunities in Paracetamol are likely to continue, and our geography expansion strategy in Europe is likely to yield higher turnover and EBITDA in future periods," Chairman Krishna Prasad Chigurupati said.
Granules, which also makes anti-inflammatory drug Ibuprofen, said 45.6 percent of its revenue came from finished dosages, the final ready-for-consumption product - its biggest segment.
Active pharmaceutical ingredients and pharmaceutical formulation intermediates contributed 35.8 percent and 18.6 percent, respectively, to the drug manufacturer's revenue.
Shares of the company climbed as much as 1.5 percent to 316.8 rupees, hitting a one-week high after the results. They declined 5.2 percent in 2022, compared with an 11.4 percent fall in the Nifty Pharma index.
Read also: Granules Pharma bags USFDA nod for ADHD drug Amphetamine Mixed Salts ER
Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
Next Story